Senate slaps Medicare on anemia drug coverage in Amgen win

Share this article:

Spurred by a strong lobbying effort by Amgen, the Senate on Tuesday called on the Centers for Medicare and Medicaid Services to reconsider its decision to restrict coverage of Epogen and Aranesp.

CMS's July move on the Amgen anemia drugs prompted major layoffs at the Thousand Oaks, CA company.

As the resolution, sponsored by Sens. Arlen Specter (R-PA) and Frank Lautenberg (D-NJ), was non-binding, it is unclear how much pressure it will place on CMS to reverse its decision.
Amgen also has the American Society of Clinical Oncology on its side. The society recently said the restriction interferes with physicians' ability to care for patients suffering from anemia.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.